The Moscow-based Gamaleya National Research Center for Epidemiology and Microbiology, under the leadership of Alexander Gintsburg, is set to kickstart clinical trials of a cancer vaccine by mid-2025.
Gintsburg anticipates initiating these trials involving cancer patients in the next year.
Presently undergoing preclinical testing on mice, the vaccine aims not only to increase the lifespan of animals with melanoma by 2-3 times but also to develop medications that ensure the definitive eradication of both tumors and metastases.
Gintsburg highlighted that upon perfecting this approach, the vaccine could significantly benefit individuals battling non-small cell lung cancer, pancreatic cancer, particular types of kidney cancer, and melanomas.
As metastases tend to emerge early in these illnesses, the vaccine holds significant promise for these patient populations.
